Cancer and necroptosis: friend or foe?

被引:63
|
作者
Philipp, Stephan [1 ]
Sosna, Justyna [1 ]
Adam, Dieter [1 ]
机构
[1] Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany
关键词
Regulated necrosis; Necroptosis; Cancer; TRAIL; TNF; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; TRAIL RECEPTOR; TNF-ALPHA; APOPTOSIS; RIP3; EXPRESSION; FADD;
D O I
10.1007/s00018-016-2193-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regulated cell death is one major factor to ensure homoeostasis in multicellular organisms. For decades, apoptosis was considered as the sole form of regulated cell death, whereas necrosis was believed to be accidental and unregulated. Due to this view, research on necrosis was somewhat neglected, especially in the field of anti-cancer treatment. However, new interest in necrosis has been sparked by the recent discovery of different forms of necrosis that show indeed regulated pathways. More and more studies now address the molecular pathways of regulated necrosis and its connections within the cellular signaling networks. Necroptosis, a subform of regulated necrosis, has so far hardly been focused on with regard to a future treatment of cancer patients and may emerge as a novel and effective approach to eliminate tumor cells. However, and similar to apoptosis, tumor cells can develop resistances against necroptosis to ensure their own survival. In this context, new molecules that enhance necroptosis are currently being identified to overcome such resistances. This review discusses cancer and necroptosis as friends or foes, i.e. the options to exploit necroptosis in anti-cancer therapies ("foes"), but also potential limitations that may block or actually cause necroptosis to act in a protumoral manner ("friends"). The balance between these two possible roles will determine whether necroptosis can indeed be used as a promising tool for early diagnosis of tumors, prevention of metastasis and anti-cancer treatment.
引用
收藏
页码:2183 / 2193
页数:11
相关论文
共 50 条
  • [31] Inflammasome: Cancer's friend or foe?
    Terlizzi, Michela
    Casolaro, Vincenzo
    Pinto, Aldo
    Sorrentino, Rosalinda
    PHARMACOLOGY & THERAPEUTICS, 2014, 143 (01) : 24 - 33
  • [32] Fibroblasts in cancer dormancy: foe or friend?
    Li Dai
    Mao Li
    Wei-long Zhang
    Ya-Jie Tang
    Ya-ling Tang
    Xin-hua Liang
    Cancer Cell International, 21
  • [33] Estrogen in Prostate Cancer - Friend or Foe?
    Corey, Eva
    CURRENT CANCER THERAPY REVIEWS, 2006, 2 (04) : 341 - 349
  • [34] Rho GTPases in cancer: friend or foe?
    Julius H. Svensmark
    Cord Brakebusch
    Oncogene, 2019, 38 : 7447 - 7456
  • [35] Folic acid: friend or foe in cancer therapy
    Thabet, Romany H.
    Alessa, Raneem Eid Mustafa
    Al-Smadi, Zahraa Khaldoon Khaleel
    Alshatnawi, Banah Saleh Gabr
    Amayreh, Batool Mahmoud Ibrahim
    Al-Dwaaghreh, Renad Bilal Ahmad
    Salah, Sereen Khalid Ahmad
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2024, 52 (01)
  • [36] 17β-estradiol in colorectal cancer: friend or foe?
    Wu, Zihong
    Xiao, Chong
    Wang, Jiamei
    Zhou, Min
    You, Fengming
    Li, Xueke
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [37] Sestrin2 in cancer: a foe or a friend?
    Ala, Moein
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [38] Friend not foe
    Ogden, Lesley Evans
    NEW SCIENTIST, 2018, 237 (3164) : 24 - 25
  • [39] Friend or foe?
    Lawton, Graham
    NEW SCIENTIST, 2011, 212 (2841) : 46 - 49
  • [40] Friend and foe
    Senellart, Michel
    ASTERION-PHILOSOPHIE HISTOIRE DES IDEES PENSEE POLITIQUE, 2009, (06):